Pursuant to Regulation 30(9) read with Schedule III of the Securities and Exchange Board of India (‘SEBI’) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the ‘Listing Regulations’), as amended, Rossari Biotech has informed the Board of Directors of Unitop Chemicals, a material subsidiary (the ‘Subsidiary’) of the Company, at their meeting held on April 03, 2026, approved sale of its office premises located at Saki Naka, Mumbai at a consideration of ~ Rs. 10 crores. The proposed transaction is expected to be completed by end of Q2 FY27. As no business operations are conducted from the premises proposed to be sold by the Subsidiary, the sale will not have any impact on the Company’s or Subsidiary’s business operations. Further, the sale of the said premises does not constitute the sale of an undertaking within the meaning of Section 180(1)(a) of the Companies Act, 2013. The details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 shall be provided on execution of the agreement.
The above information is a part of company’s filings submitted to BSE.
